Last reviewed · How we verify
NCT06125782
Effect of Omega-3 Fatty Acid on Neurobehavioral Status of Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo Controlled Trial
Phase 2 trial testing Omega 3 fatty acid in Autism Spectrum Disorder in 64 participants. Completed in 5 February 2024.
30 January 2024
Quick facts
| Lead sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 19 September 2023 |
| Primary completion | 30 January 2024 |
| Estimated completion | 5 February 2024 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- Omega 3 fatty acid — full drug profile →
- Placebo of Omega-3 fatty acid softgel capsule — full drug profile →
Conditions studied
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Who can join
Adults 2 to 18, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is conducted to assess whether Omega-3 fatty acid improves neurobehavioral staus of children with Autism Spectrum Disorder and whether there is any correlation of this improvement with reference range of Omega-3 fatty acid.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06125782
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Omega 3 fatty acid
Trials testing the same drug.
- NCT05529576 — Multi-factor Model Constraction for Early Warning and Diagnosis of MDD · Phase 4 · unknown
- NCT05005806 — Fish Oil (Omega 3 ) in Sjogren's Syndrome · Phase 2, PHASE3 · completed
- NCT04836052 — Omega-3 Oil Use in COVID-19 Patients in Qatar · Phase 3 · unknown
- NCT04181593 — Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease · Phase 3 · completed
- NCT03936621 — Efficacy and Safety of Omega 3 Fatty Acid Supplements on Heavy Smokers · Phase 2 · unknown
Other recruiting trials for Autism Spectrum Disorder
Currently open trials in the same condition.
- NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi · NA · recruiting
- NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre · NA · recruiting
- NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design · EARLY_PHASE1 · recruiting
Other Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh trials
Trials by the same sponsor.
- NCT07507045 — Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh · NA · not yet recruiting
- NCT07537634 — Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication · Phase 4 · not yet recruiting
- NCT07161336 — Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA · Phase 2 · recruiting
- NCT06960694 — Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis · Phase 2 · completed
- NCT07123922 — Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patient · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06125782 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06125782.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing